세계의 괴사성 리포이드카(NL) 시장 보고서(2025년)

Necrobiosis Lipodica (NL) Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 괴사성 리포이드카 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.7%로 56억 5,000만 달러로 성장할 것으로 보입니다. 예측기간의 성장은 고령화 인구 증가, 피부 건강과 미용에 대한 의식 증가, 가처분 소득 증가, 피부의 건강에 대한 의식 증가, 정부 이니셔티브의 상승 등의 요인에 의해 초래됩니다. 이 기간에 예상되는 주요 동향으로는 치료 선택의 진보, 진단 기술의 향상, 생물 제제의 채용, 임상 검사의 진전, 재생 요법의 출현 등이 있습니다.

당뇨병의 이환율 증가는 향후 리포이드 괴사증(NL) 시장의 성장을 가속할 것으로 예측됩니다. 당뇨병은 인슐린 분비 부족과 인슐린 저항성으로 인해 신체가 혈당 조절에 어려움을 겪는 만성 질환으로 다양한 건강 합병증을 유발할 수 있습니다. 당뇨병 환자 증가는 앉기 쉬운 라이프 스타일, 식생활의 혼란, 유전적 소인에 의한 점이 큽니다. 신체 활동의 저하, 과도한 스크린 타임 등을 특징으로 하는 현대의 라이프 스타일은 비만과 인슐린 저항성을 조장하고 있습니다. 당뇨병으로 혈당이 높아지면, 가는 혈관에 장애가 일어나(미소혈관증), 혈행 불량, 산소의 감소, 피부에의 영양 공급의 저하를 초래합니다. 그 결과 피부가 부상을 입기 쉽고 치유가 지연됩니다. 그 결과 피부 조직이 변성되어 NL에 노란색 위축이 형성됩니다. 2023년 10월 국민보건서비스(National Health Service)의 보고에 따르면 잉글랜드에서 1형 당뇨병의 유병률은 2021년 26만 1,710건에서 2022년 27만 935건으로 증가하여 전년대비 3.5% 증가했습니다. 따라서 당뇨병 환자 수 증가는 괴사성 리포이드카 시장의 성장을 가속하고 있습니다.

자가면역 질환의 이환율 증가는 또한 괴사성 리포이드카 시장의 성장을 가속할 것으로 예측됩니다. 2024년 11월에 Versorgungsatlas가 발표한 바에 따르면 독일의 피보험자 7,324만 1,305명 중, 2022년에는 630만 4,340명이 적어도 하나의 자가면역질환으로 진단되었으며, 유병률은 8.61%였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 괴사성 리포이드카(NL) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 괴사성 리포이드카(NL) 시장 : 성장률 분석
• 세계의 괴사성 리포이드카(NL) 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 괴사성 리포이드카(NL) 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 괴사성 리포이드카(NL) 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 괴사성 리포이드카(NL) 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 치료
• 약
• 기타
• 세계의 괴사성 리포이드카(NL) 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 국소
• 비경구
• 기타
• 세계의 괴사성 리포이드카(NL) 시장 : 진단별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 피부 생검
• 조직병리학
• 기타
• 세계의 괴사성 리포이드카(NL) 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 온라인 약국
• 소매 약국
• 세계의 괴사성 리포이드카(NL) 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 재택치료
• 전문 클리닉
• 기타
• 세계의 괴사성 리포이드카(NL) 시장 : 치료법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 광선요법
• 레이저 요법
• 상처 케어 및 압박 요법
• 물리치료 및 재활
• 세계의 괴사성 리포이드카(NL) 시장 : 약제별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 국소 코르티코스테로이드
• 병변 내 코르티코 스테로이드
• 전신성 코르티코스테로이드
• 면역조절제
• 생물제제
• 항혈소판제
• 항산화 물질과 혈관 확대제
• 항생제
• 세계의 괴사성 리포이드카(NL) 시장 : 기타 치료법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 수술 절제 및 피부 이식
• 고압 산소 요법(HBOT)
• 다혈소판 혈장 요법
• 줄기세포요법 및 재생의료
• 대체요법 및 허브요법

제7장 지역별/국가별 분석

• 세계의 괴사성 리포이드카(NL) 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 괴사성 리포이드카(NL) 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 괴사성 리포이드카(NL) 시장 : 경쟁 구도
• 괴사성 리포이드카(NL) 시장 : 기업 프로파일
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA

제31장 기타 주요 기업 및 혁신 기업

• GlaxoSmithKline plc
• Eli Lilly and Company
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Limited
• Bausch Health Companies Inc.
• Galderma Laboratories LP
• Dr. Reddy's Laboratories Ltd.
• Incyte Pharmaceuticals
• Celltrion Healthcare Co. Ltd.
• Almirall SA
• Samsung Bioepis Co. Ltd.
• Hovione
• Momenta Pharmaceuticals Inc.
• HanAll Biopharma Co. Ltd.
• Processa Pharmaceuticals

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 괴사성 리포이드카(NL) 시장(2029년) : 새로운 기회를 제공하는 국가
• 괴사성 리포이드카(NL) 시장(2029년) : 새로운 기회를 제공하는 부문
• 괴사성 리포이드카(NL) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

JHS

영문 목차

영문목차

Necrobiosis lipoidica is a rare, chronic skin condition marked by yellowish, atrophic plaques with prominent blood vessels, most often appearing on the shins. It is associated with collagen degeneration, inflammation, and lipid accumulation within the skin.

The primary treatment options for necrobiosis lipoidica (NL) include therapies, medications, and other interventions. Therapy refers to treatments aimed at alleviating or healing the condition, often incorporating medical, psychological, or physical approaches. These treatments can be administered through various routes, including oral, topical, parenteral, and other methods. The diagnosis of NL is typically made using techniques such as skin biopsy, histopathology, and other diagnostic procedures. Treatments are distributed via channels such as hospital pharmacies, online pharmacies, and retail pharmacies. Additionally, the end users of these treatments include hospitals, home care settings, specialty clinics, and other healthcare providers.

The necrobiosis lipoidica (NL) market research report is one of a series of new reports from The Business Research Company that provides necrobiosis lipoidica (NL) market statistics, including the necrobiosis lipoidica (NL) industry global market size, regional shares, competitors with the necrobiosis lipoidica (NL) market share, detailed necrobiosis lipoidica (NL) market segments, market trends, and opportunities, and any further data you may need to thrive in the necrobiosis lipoidica (NL) industry. This necrobiosis lipoidica (NL) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The necrobiosis lipoidica market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth observed in the historical period can be attributed to factors such as the rising number of diabetes cases, the increasing prevalence of skin infections, higher healthcare spending, a growing incidence of cancer, and greater awareness of the disease.

The necrobiosis lipoidica market size is expected to see strong growth in the next few years. It will grow to $5.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The projected growth for the forecast period is driven by factors such as the increasing aging population, rising awareness of skin health and aesthetics, higher disposable incomes, growing awareness of skin health, and the rise of government initiatives. Key trends expected during this period include advancements in treatment options, improvements in diagnostic techniques, the adoption of biologics, progress in clinical trials, and the emergence of regenerative therapies.

The rising incidence of diabetes is expected to drive the growth of the necrobiosis lipoidica (NL) market in the future. Diabetes is a chronic condition where the body struggles to regulate blood sugar due to insufficient insulin production or insulin resistance, which can lead to various health complications. The increase in diabetes cases is largely attributed to sedentary lifestyles, poor diets, and genetic predisposition. Modern lifestyles, characterized by prolonged sitting, reduced physical activity, and excessive screen time, contribute to obesity and insulin resistance. High blood sugar levels in diabetes cause damage to small blood vessels (microangiopathy), which leads to poor circulation, reduced oxygen, and nutrient supply to the skin. This makes the skin more vulnerable to injury and delayed healing. As a result, skin tissue degenerates, contributing to the formation of yellowish, atrophic plaques in NL. For example, in October 2023, the National Health Service reported that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2021 to 270,935 cases in 2022, marking a 3.5% increase year-over-year. Therefore, the growing number of diabetes cases is fueling the growth of the necrobiosis lipoidica market.

The increasing incidence of autoimmune diseases is also expected to drive the growth of the necrobiosis lipoidica market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is influenced by factors such as genetic predisposition, environmental triggers, and lifestyle changes that affect immune system behavior. These diseases contribute to NL by causing chronic inflammation and immune dysfunction, which leads to collagen degeneration and impaired skin healing. For instance, in November 2024, Versorgungsatlas reported that, among 73,241,305 insured individuals in Germany, 6,304,340 were diagnosed with at least one autoimmune disease in 2022, resulting in a raw prevalence rate of 8.61%. This rising incidence of autoimmune diseases is driving the growth of the necrobiosis lipoidica market.

Leading companies in the necrobiosis lipoidica market are focusing on innovative solutions, such as developing websites for patient education, to enhance diagnosis, treatment accessibility, and disease management. Websites are digital platforms that provide information, services, or interactive features accessible via the internet. For example, in August 2022, Processa Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, launched Necrobiosislipoidicastudy.com, a website designed to raise awareness about ulcerative necrobiosis lipoidica (uNL), a rare dermatological condition. The platform provides information on the ongoing Phase 2 clinical trial evaluating PCS499 as a potential treatment for uNL, furthering the company's commitment to advancing innovative therapies for underserved patient populations.

Major players in the necrobiosis lipodica (nl) market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Bausch Health Companies Inc., Galderma Laboratories L.P., Dr. Reddy's Laboratories Ltd., Incyte Pharmaceuticals, Celltrion Healthcare Co. Ltd., Almirall S.A., Samsung Bioepis Co. Ltd., Hovione, Momenta Pharmaceuticals Inc., HanAll Biopharma Co. Ltd., Processa Pharmaceuticals.

North America was the largest region in the necrobiosis lipoidica market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in necrobiosis lipoidica (NL) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the necrobiosis lipoidica (NL) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The necrobiosis lipoidica (NL) market consists of revenues earned by entities by provide services such as dermatology consultation, wound care services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrobiosis lipoidica market includes sales of corticosteroids, immunomodulators, corticosteroid creams, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Necrobiosis Lipodica (NL) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on necrobiosis lipodica (nl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for necrobiosis lipodica (nl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The necrobiosis lipodica (nl) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Therapy; Drugs; Other Treatments
• 2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration
• 3) By Diagnosis: Skin Biopsy; Histopathology; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Therapy: Phototherapy; Laser Therapy; Wound Care And Compression Therapy; Physical Therapy And Rehabilitation
• 2) By Drugs: Topical Corticosteroids; Intralesional Corticosteroids; Systemic Corticosteroids; Immunomodulators; Biologics; Antiplatelet Agents; Antioxidants And Vasodilators; Antibiotics
• 3) By Other Treatments: Surgical Excision And Skin Grafting; Hyperbaric Oxygen Therapy (HBOT); Platelet-Rich Plasma (PRP) Therapy; Stem Cell Therapy And Regenerative Medicine; Alternative And Herbal Treatments
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Necrobiosis Lipodica (NL) Market Characteristics

3. Necrobiosis Lipodica (NL) Market Trends And Strategies

4. Necrobiosis Lipodica (NL) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Necrobiosis Lipodica (NL) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Necrobiosis Lipodica (NL) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Necrobiosis Lipodica (NL) Market Growth Rate Analysis
• 5.4. Global Necrobiosis Lipodica (NL) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Necrobiosis Lipodica (NL) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Necrobiosis Lipodica (NL) Total Addressable Market (TAM)

6. Necrobiosis Lipodica (NL) Market Segmentation

• 6.1. Global Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapy
• Drugs
• Other Treatments
• 6.2. Global Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• Parenteral
• Other Routes Of Administration
• 6.3. Global Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Skin Biopsy
• Histopathology
• Other Diagnosis
• 6.4. Global Necrobiosis Lipodica (NL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Necrobiosis Lipodica (NL) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Necrobiosis Lipodica (NL) Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phototherapy
• Laser Therapy
• Wound Care And Compression Therapy
• Physical Therapy And Rehabilitation
• 6.7. Global Necrobiosis Lipodica (NL) Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids
• Intralesional Corticosteroids
• Systemic Corticosteroids
• Immunomodulators
• Biologics
• Antiplatelet Agents
• Antioxidants And Vasodilators
• Antibiotics
• 6.8. Global Necrobiosis Lipodica (NL) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Excision And Skin Grafting
• Hyperbaric Oxygen Therapy (HBOT)
• Platelet-Rich Plasma (PRP) Therapy
• Stem Cell Therapy And Regenerative Medicine
• Alternative And Herbal Treatments

7. Necrobiosis Lipodica (NL) Market Regional And Country Analysis

• 7.1. Global Necrobiosis Lipodica (NL) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Necrobiosis Lipodica (NL) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Necrobiosis Lipodica (NL) Market

• 8.1. Asia-Pacific Necrobiosis Lipodica (NL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Necrobiosis Lipodica (NL) Market

• 9.1. China Necrobiosis Lipodica (NL) Market Overview
• 9.2. China Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Necrobiosis Lipodica (NL) Market

• 10.1. India Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Necrobiosis Lipodica (NL) Market

• 11.1. Japan Necrobiosis Lipodica (NL) Market Overview
• 11.2. Japan Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Necrobiosis Lipodica (NL) Market

• 12.1. Australia Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Necrobiosis Lipodica (NL) Market

• 13.1. Indonesia Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Necrobiosis Lipodica (NL) Market

• 14.1. South Korea Necrobiosis Lipodica (NL) Market Overview
• 14.2. South Korea Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Necrobiosis Lipodica (NL) Market

• 15.1. Western Europe Necrobiosis Lipodica (NL) Market Overview
• 15.2. Western Europe Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Necrobiosis Lipodica (NL) Market

• 16.1. UK Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Necrobiosis Lipodica (NL) Market

• 17.1. Germany Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Necrobiosis Lipodica (NL) Market

• 18.1. France Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Necrobiosis Lipodica (NL) Market

• 19.1. Italy Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Necrobiosis Lipodica (NL) Market

• 20.1. Spain Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Necrobiosis Lipodica (NL) Market

• 21.1. Eastern Europe Necrobiosis Lipodica (NL) Market Overview
• 21.2. Eastern Europe Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Necrobiosis Lipodica (NL) Market

• 22.1. Russia Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Necrobiosis Lipodica (NL) Market

• 23.1. North America Necrobiosis Lipodica (NL) Market Overview
• 23.2. North America Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Necrobiosis Lipodica (NL) Market

• 24.1. USA Necrobiosis Lipodica (NL) Market Overview
• 24.2. USA Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Necrobiosis Lipodica (NL) Market

• 25.1. Canada Necrobiosis Lipodica (NL) Market Overview
• 25.2. Canada Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Necrobiosis Lipodica (NL) Market

• 26.1. South America Necrobiosis Lipodica (NL) Market Overview
• 26.2. South America Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Necrobiosis Lipodica (NL) Market

• 27.1. Brazil Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Necrobiosis Lipodica (NL) Market

• 28.1. Middle East Necrobiosis Lipodica (NL) Market Overview
• 28.2. Middle East Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Necrobiosis Lipodica (NL) Market

• 29.1. Africa Necrobiosis Lipodica (NL) Market Overview
• 29.2. Africa Necrobiosis Lipodica (NL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Necrobiosis Lipodica (NL) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Necrobiosis Lipodica (NL) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Necrobiosis Lipodica (NL) Market Competitive Landscape And Company Profiles

• 30.1. Necrobiosis Lipodica (NL) Market Competitive Landscape
• 30.2. Necrobiosis Lipodica (NL) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Necrobiosis Lipodica (NL) Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Eli Lilly and Company
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Daiichi Sankyo Company Limited
• 31.5. Bausch Health Companies Inc.
• 31.6. Galderma Laboratories L.P.
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Incyte Pharmaceuticals
• 31.9. Celltrion Healthcare Co. Ltd.
• 31.10. Almirall S.A.
• 31.11. Samsung Bioepis Co. Ltd.
• 31.12. Hovione
• 31.13. Momenta Pharmaceuticals Inc.
• 31.14. HanAll Biopharma Co. Ltd.
• 31.15. Processa Pharmaceuticals

32. Global Necrobiosis Lipodica (NL) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Necrobiosis Lipodica (NL) Market

34. Recent Developments In The Necrobiosis Lipodica (NL) Market

35. Necrobiosis Lipodica (NL) Market High Potential Countries, Segments and Strategies

• 35.1 Necrobiosis Lipodica (NL) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Necrobiosis Lipodica (NL) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Necrobiosis Lipodica (NL) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료